Current status of the treatment of chronic hepatitis B-related liver fibrosis/cirrhosis

Jiandan QIAN; Hong ZHAO; Guiqiang WANG

doi:10.3969/j.issn.1001-5256.2021.12.036

Volume 37 Issue 12

Dec. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(12): 2909-2913

PDF( 1901 KB)

Current status of the treatment of chronic hepatitis B-related liver fibrosis/cirrhosis

DOI: 10.3969/j.issn.1001-5256.2021.12.036

Department of Infectious Diseases and Center for Liver Diseases, Peking University First Hospital, Beijing 100034, China

Research funding:

China Mega-Project for Infectious Diseases (2017ZX10203202)

Received Date: 2021-05-08
Accepted Date: 2021-06-11
Published Date: 2021-12-20

Abstract

Abstract

Chronic hepatitis B (CHB) liver fibrosis is the process of liver tissue damage and repair caused by hepatitis B virus (HBV) infection and may develop into liver cirrhosis in severe cases, and there are still no specific drugs for the treatment of this disease. This article summarizes the main targets involved in the development and progression of CHB liver fibrosis, such as hepatic stellate cell activation, inflammation, and gut-liver axis, as well as the signal transduction pathways associated with fibrosis, and targeting these targets may have a certain anti-fibrogenic effect. At present, anti-HBV therapy combined with or followed by anti-fibrotic therapy can delay or even reverse liver fibrosis/cirrhosis in some patients; however, the reversal of advanced liver fibrosis/cirrhosis still faces great challenges, and there is still no consensus on the timing of combined or sequential therapy. It is believed that identification of therapeutic targets highly associated with CHB liver fibrosis/cirrhosis and combination therapy with compounds targeting multiple pathways associated with liver fibrosis will become the focus of future research.
- Hepatitis B, Chronic,
- Liver Cirrhosis,
- Therapeutics

FullText(HTML)

References(45)

References

[1]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[2]	VITTAL A, GHANY MG. WHO guidelines for prevention, care and treatment of individuals infected with HBV: A US perspective[J]. Clin Liver Dis, 2019, 23(3): 417-432. DOI: 10.1016/j.cld.2019.04.008.
[3]	YOON YJ, FRIEDMAN SL, LEE YA. Antifibrotic therapies: Where are we now?[J]. Semin Liver Dis, 2016, 36(1): 87-98. DOI: 10.1055/s-0036-1571295.
[4]	ROEHLEN N, CROUCHET E, BAUMERT TF. Liver fibrosis: Mechanistic concepts and therapeutic perspectives[J]. Cells, 2020, 9(4): 875. DOI: 10.3390/cells9040875.
[5]	HENDERSON NC, RIEDER F, WYNN TA. Fibrosis: From mechanisms to medicines[J]. Nature, 2020, 587(7835): 555-566. DOI: 10.1038/s41586-020-2938-9.
[6]	LEVRERO M, ZUCMAN-ROSSI J. Mechanisms of HBV-induced hepatocellular carcinoma[J]. J Hepatol, 2016, 64(1 Suppl): S84-S84, S101. DOI: 10.1016/j.jhep.2016.02.021.
[7]	GONG J, TU W, HAN J, et al. Hepatic SATB1 induces paracrine activation of hepatic stellate cells and is upregulated by HBx[J]. Sci Rep, 2016, 6: 37717. DOI: 10.1038/srep37717.
[8]	LIU X, ZHU ST, YOU H, et al. Hepatitis B virus infects hepatic stellate cells and affects their proliferation and expression of collagen type I[J]. Chin Med J (Engl), 2009, 122(12): 1455-1461. http://www.cqvip.com/QK/85656X/200912/30712357.html
[9]	KRENKEL O, TACKE F. Liver macrophages in tissue homeostasis and disease[J]. Nat Rev Immunol, 2017, 17(5): 306-321. DOI: 10.1038/nri.2017.11.
[10]	WYNN TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases[J]. J Clin Invest, 2007, 117(3): 524-529. DOI: 10.1172/JCI31487.
[11]	LUEDDE T, KAPLOWITZ N, SCHWABE RF. Cell death and cell death responses in liver disease: Mechanisms and clinical relevance[J]. Gastroenterology, 2014, 147(4): 765-783. e4. DOI: 10.1053/j.gastro.2014.07.018.
[12]	MENG F, WANG K, AOYAMA T, et al. Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice[J]. Gastroenterology, 2012, 143(3): 765-776. e3. DOI: 10.1053/j.gastro.2012.05.049.
[13]	CHEN DB, WANG K, WANG HN, et al. Therapeutic potential of human umbilical cord-derived mesenchy-mal stem cells in the treatment of CCl₄ induced liver fibrosis[J]. Letters in Biotechnology, 2013, 3: 347-350. DOI: 10.3969/j.issn.1009-0002.2013.03.011. 陈冬波, 王科, 王慧娜, 等. 人脐带间充质干细胞对CCl₄诱导肝纤维化的治疗作用研究[J]. 生物技术通讯, 2013, 3: 347-350. DOI: 10.3969/j.issn.1009-0002.2013.03.011.
[14]	WANG J, WANG Y, ZHANG X, et al. Gut microbial dysbiosis is associated with altered hepatic functions and serum metabolites in chronic hepatitis B patients[J]. Front Microbiol, 2017, 8: 2222. DOI: 10.3389/fmicb.2017.02222.
[15]	CHOU HH, CHIEN WH, WU LL, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota[J]. Proc Natl Acad Sci U S A, 2015, 112(7): 2175-2180. DOI: 10.1073/pnas.1424775112.
[16]	TILG H, CANI PD, MAYER EA. Gut microbiome and liver diseases[J]. Gut, 2016, 65(12): 2035-2044. DOI: 10.1136/gutjnl-2016-312729.
[17]	CHAUHAN A, KUMAR R, SHARMA S, et al. Fecal microbiota transplantation in hepatitis B e antigen-positive chronic hepatitis B patients: A pilot study[J]. Dig Dis Sci, 2021, 66(3): 873-880. DOI: 10.1007/s10620-020-06246-x.
[18]	YING HZ, CHEN Q, ZHANG WY, et al. PDGF signaling pathway in hepatic fibrosis pathogenesis and therapeutics (Review)[J]. Mol Med Rep, 2017, 16(6): 7879-7889. DOI: 10.3892/mmr.2017.7641.
[19]	DEWIDAR B, MEYER C, DOOLEY S, et al. TGF-β in hepatic stellate cell activation and liver fibrogenesis-updated 2019[J]. Cells, 2019, 8(11). DOI: 10.3390/cells8111419.
[20]	IVANOV AV, VALUEV-ELLISTON VT, TYURINA DA, et al. Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis[J]. Oncotarget, 2017, 8(3): 3895-3932. DOI: 10.18632/oncotarget.13904.
[21]	NISHIKAWA K, OSAWA Y, KIMURA K. Wnt/β-catenin signaling as a potential target for the treatment of liver cirrhosis using antifibrotic drugs[J]. Int J Mol Sci, 2018, 19(10). DOI: 10.3390/ijms19103103.
[22]	ROCKEY DC. Liver fibrosis reversion after suppression of hepatitis B virus[J]. Clin Liver Dis, 2016, 20(4): 667-679. DOI: 10.1016/j.cld.2016.06.003.
[23]	SCHIFF ER, LEE SS, CHAO YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B[J]. Clin Gastroenterol Hepatol, 2011, 9(3): 274-276. DOI: 10.1016/j.cgh.2010.11.040.
[24]	CHANG TT, LIAW YF, WU SS, et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J]. Hepatology, 2010, 52(3): 886-893. DOI: 10.1002/hep.23785.
[25]	YOKOSUKA O, TAKAGUCHI K, FUJIOKA S, et al. Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection[J]. J Hepatol, 2010, 52(6): 791-799. DOI: 10.1016/j.jhep.2009.12.036.
[26]	WU SD, LIU LL, CHENG JL, et al. Longitudinal monitoring of liver fibrosis status by transient elastography in chronic hepatitis B patients during long-term entecavir treatment[J]. Clin Exp Med, 2018, 18(3): 433-443. DOI: 10.1007/s10238-018-0501-x.
[27]	MARCELLIN P, GANE E, BUTI M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study[J]. Lancet, 2013, 381(9865): 468-475. DOI: 10.1016/S0140-6736(12)61425-1.
[28]	POYNARD T, MASSARD J, RUDLER M, et al. Impact of interferon-alpha treatment on liver fibrosis in patients with chronic hepatitis B: An overview of published trials[J]. Gastroenterol Clin Biol, 2009, 33(10-11): 916-922. DOI: 10.1016/j.gcb.2009.06.006.
[29]	ZOUTENDIJK R, REIJNDERS JG, ZOULIM F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J]. Gut, 2013, 62(5): 760-765. DOI: 10.1136/gutjnl-2012-302024.
[30]	RAMACHANDRAN P, HENDERSON NC. Antifibrotics in chronic liver disease: Tractable targets and translational challenges[J]. Lancet Gastroenterol Hepatol, 2016, 1(4): 328-340. DOI: 10.1016/S2468-1253(16)30110-8.
[31]	WENG HL, CAI WM, LIU RH. Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis[J]. World J Gastroenterol, 2001, 7(1): 42-48. DOI: 10.3748/wjg.v7.i1.42.
[32]	WU YJ, CAI WM, LI Q, et al. Long-term antifibrotic action of interferon-γ treatment in patients with chronic hepatitis B virus infection[J]. Hepatobiliary Pancreat Dis Int, 2011, 10(2): 151-157. DOI: 10.1016/s1499-3872(11)60024-6.
[33]	LI H. Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula[J]. J Ethnopharmacol, 2020, 251: 112442. DOI: 10.1016/j.jep.2019.112442.
[34]	CHEN LJ, TANG H. Meta-analysis of the efficacy of fufangbiejiaruangan tablets combined with entecavir in the treatment of chronic hepatitis B liver fibrosis[J]. Gansu Med, 2018, 37(8): 678-680, 696. https://www.cnki.com.cn/Article/CJFDTOTAL-GSYY201808004.htm 陈丽津, 汤浩. 复方鳖甲软肝片联合恩替卡韦治疗慢性乙型肝炎肝纤维化疗效Meta分析[J]. 甘肃医药, 2018, 37(8): 678-680, 696. https://www.cnki.com.cn/Article/CJFDTOTAL-GSYY201808004.htm
[35]	RONG G, CHEN Y, YU Z, et al. Synergistic effect of biejia-ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: A multicenter, randomized, double-blinded, placebo-controlled trial[J]. J Infect Dis, 2020. DOI: 10.1093/infdis/jiaa266.[Online ahead of print]
[36]	LIAO QY, GUAN R, JIANG YX, et al. Systematic evaluation of compound biejia ruangan tablets combined with entecavir in the treatment of chronic hepatitis B complicated with hepatic fibrosis[J]. Eval Anal Drug-Use Hosp China, 2019, 19(9): 1031-1038. DOI: 10.14009/j.issn.1672-2124.2019.09.002. 廖庆英, 关蓉, 蒋吟啸, 等. 复方鳖甲软肝片联合恩替卡韦治疗慢性乙型病毒性肝炎伴肝纤维化的系统评价[J]. 中国医院用药评价与分析, 2019, 19(9): 1031-1038. DOI: 10.14009/j.issn.1672-2124.2019.09.002.
[37]	LIU HL, LV J, ZHAO ZM, et al. Fuzhenghuayu decoction ameliorates hepatic fibrosis by attenuating experimental sinusoidal capillarization and liver angiogenesis[J]. Sci Rep, 2019, 9(1): 18719. DOI: 10.1038/s41598-019-54663-4.
[38]	WANG QL, TAO YY, SHEN L, et al. Chinese herbal medicine Fuzheng Huayu recipe inhibits liver fibrosis by mediating the transforming growth factor-beta1/Smads signaling pathway[J]. J Chin Integr Med, 2012, 10(5): 561-568. DOI: 10.3736/jcim20120512. 王清兰, 陶艳艳, 沈丽, 等. 扶正化瘀方影响转化生长因子β1/Smad信号通路的抗肝纤维化作用机制[J]. 中西医结合学报, 2012, 10(5): 561-568. DOI: 10.3736/jcim20120512.
[39]	LIU P, HU YY, LIU C, et al. Multicenter clinical study on Fuzhenghuayu capsule against liver fibrosis due to chronic hepatitis B[J]. World J Gastroenterol, 2005, 11(19): 2892-2899. DOI: 10.3748/wjg.v11.i19.2892.
[40]	CHEN Y, ZHAO Z, FAN H, et al. Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: Study protocol for a single arm clinical objective performance criteria trial[J]. Contemp Clin Trials Commun, 2020, 19: 100601. DOI: 10.1016/j.conctc.2020.100601.
[41]	MA X, LIAO QY, HE X, et al. Systematic review on fuzhenghuayu capsules combined with entecavir in the treatment of liver fibrosis induced by chronic hepatitis B[J]. Eval Anal Drug-Use Hosp China, 2019, 19(12): 1413-1419. DOI: 10.14009/j.issn.1672-2124.2019.12.002. 马骁, 廖庆英, 何璇, 等. 扶正化瘀胶囊联合恩替卡韦治疗慢性乙型肝炎肝纤维化的系统评价[J]. 中国医院用药评价与分析, 2019, 19(12): 1413-1419. DOI: 10.14009/j.issn.1672-2124.2019.12.002.
[42]	CHEN PL, HUANG GY, CUI YY, et al. A meta-analysis of Fuzheng huayu capsule combined with entecavir in the treatment of hepatitis B cirrhosis[J]. Chin J Integr Tradit West Med Liver Diss, 2021, 31(1): 63-69. DOI: 10.3969/j.issn.1005-0264.2021.01.018. 陈鹏兰, 黄古叶, 崔亚运, 等. 扶正化瘀胶囊联合恩替卡韦治疗乙型肝炎肝硬化的Meta分析[J]. 中西医结合肝病杂志, 2021, 31(1): 63-69. DOI: 10.3969/j.issn.1005-0264.2021.01.018.
[43]	HUANG ZQ. Meta-analysis of therapeutic effects of anluohuaxianwan on hepatic fibrosis[J]. Chin J Drug Evaln, 2015, (1): 41-44. DOI: 10.3969/j.issn.2095-3593.2015.01.013. 黄志巧. 安络化纤丸抗肝纤维化疗效的Meta分析[J]. 中国药物评价, 2015, (1): 41-44. DOI: 10.3969/j.issn.2095-3593.2015.01.013.
[44]	MIAO L, YANG WN, DONG XQ, et al. Combined anluohuaxianwan and entecavir treatment significantly improve the improvement rate of liver fibrosis in patients with chronic hepatitis B virus infection[J]. Chin J Hepatol, 2019, 27(7): 521-526. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.009. 苗亮, 杨婉娜, 董晓琴, 等. 安络化纤丸联合恩替卡韦治疗可显著提高慢性乙型肝炎病毒感染者肝纤维化的改善率[J]. 中华肝脏病杂志, 2019, 27(7): 521-526. DOI: 10.3760/cma.j.issn.1007-3418.2019.07.009.
[45]	ZONG J, ZHOU JF. Effect of Anluo Hua Xian pill combined with pegylated interferon α-2a on liver function and liver fibrosis in patients with chronic hepatitis B with liver fibrosis[J]. J Clin Res, 2019, 36(4): 771-773. DOI: 10.3969/j.issn.1671-7171.2019.04.054. 宗杰, 周建飞. 安络化纤丸联合聚乙二醇干扰素α-2a对慢性乙肝肝纤维化患者肝功能及肝纤维化的影响[J]. 医学临床研究, 2019, 36(4): 771-773. DOI: 10.3969/j.issn.1671-7171.2019.04.054.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (679) PDF downloads(136)

Current status of the treatment of chronic hepatitis B-related liver fibrosis/cirrhosis

DOI: 10.3969/j.issn.1001-5256.2021.12.036

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Current status of the treatment of chronic hepatitis B-related liver fibrosis/cirrhosis

DOI: 10.3969/j.issn.1001-5256.2021.12.036

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content